LAG-3 Fills a Complex Role in the Immune System
OncLive,
The LAG-3 pathway has emerged as the next target for the use of immune checkpoint inhibitors in oncology.
The LAG-3 pathway has emerged as the next target for the use of immune checkpoint inhibitors in oncology.
The Food and Drug Administration has approved a combination nivolumab/relatlimab-rmbw immune checkpoint inhibitor (Opdualag…
The Food and Drug Administration on Friday approved a new type of immunotherapy for skin cancer that's spread to other parts of…
The FDA tonight approved a combination nivolumab/relatlimab-rmbw immune checkpoint inhibitor (Opdualag) for unresectable or…